Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment.

PubWeight™: 4.16‹?› | Rank: Top 1%

🔗 View Article (PMID 15295046)

Published in N Engl J Med on August 05, 2004


Amy Holleman1, Meyling H Cheok, Monique L den Boer, Wenjian Yang, Anjo J P Veerman, Karin M Kazemier, Deqing Pei, Cheng Cheng, Ching-Hon Pui, Mary V Relling, Gritta E Janka-Schaub, Rob Pieters, William E Evans

Author Affiliations

1: Division of Pediatric Oncology-Hematology, Erasmus University Medical Center, Sophia Children's Hospital, Rotterdam, The Netherlands.

Articles citing this

(truncated to the top 100)

Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med (2011) 5.77

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol (2009) 5.22

A hypothesis on the origin and evolution of the response to inhaled anesthetics. Anesth Analg (2008) 3.55

Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood (2009) 2.86

Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]. J Clin Oncol (2008) 2.51

A multivariate approach for integrating genome-wide expression data and biological knowledge. Bioinformatics (2006) 2.42

Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA (2015) 2.20

A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. Blood (2007) 2.19

The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18

BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood (2007) 2.12

Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest (2007) 2.05

Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. Cancer Res (2009) 2.03

Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. Blood (2007) 1.97

Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest (2010) 1.97

Pharmacogenomic discovery using cell-based models. Pharmacol Rev (2009) 1.96

Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood (2012) 1.90

Personalized exposure assessment: promising approaches for human environmental health research. Environ Health Perspect (2005) 1.83

Asparagine synthetase chemotherapy. Annu Rev Biochem (2006) 1.82

Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex. Cancer Res (2009) 1.82

Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood (2008) 1.79

Adult acute lymphoblastic leukemia: concepts and strategies. Cancer (2010) 1.78

Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood (2008) 1.67

Complex genomic alterations and gene expression in acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Proc Natl Acad Sci U S A (2006) 1.63

STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress. Proc Natl Acad Sci U S A (2010) 1.55

Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol (2010) 1.49

Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. Blood (2006) 1.41

Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin (2009) 1.39

In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med (2008) 1.37

Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies. Biochem J (2006) 1.31

Asparagine synthetase: regulation by cell stress and involvement in tumor biology. Am J Physiol Endocrinol Metab (2013) 1.26

Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol (2015) 1.26

Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther (2007) 1.25

The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood (2005) 1.25

MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica (2011) 1.21

Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2007) 1.19

Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis. PLoS One (2012) 1.19

Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia. Haematologica (2010) 1.19

Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer (2008) 1.18

GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy. Cell Death Dis (2010) 1.17

TCR-dependent transformation of mature memory phenotype T cells in mice. J Clin Invest (2011) 1.13

Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma. Clin Cancer Res (2008) 1.13

Peripheral blood gene expression profiles in metabolic syndrome, coronary artery disease and type 2 diabetes. Genes Immun (2011) 1.12

A new method for class prediction based on signed-rank algorithms applied to Affymetrix microarray experiments. BMC Bioinformatics (2008) 1.11

False discovery rate paradigms for statistical analyses of microarray gene expression data. Bioinformation (2007) 1.07

Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism. Br J Cancer (2009) 1.04

The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia. J Natl Cancer Inst (2008) 1.04

A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. Leukemia (2010) 1.03

Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine. Am J Drug Alcohol Abuse (2009) 1.02

NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nat Genet (2015) 1.02

Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. World J Gastroenterol (2011) 1.01

ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia. Blood (2011) 1.01

Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther (2011) 1.00

Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential. J Exp Med (2014) 0.99

Insights into gene expression changes impacting B-cell transformation: cross-species microarray analysis of bovine leukemia virus tax-responsive genes in ovine B cells. J Virol (2006) 0.98

Molecular pathway identification using biological network-regularized logistic models. BMC Genomics (2013) 0.98

Clinical proteomics: present and future prospects. Clin Biochem Rev (2006) 0.97

The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica (2016) 0.97

Expression of the outcome predictor in acute leukemia 1 (OPAL1) gene is not an independent prognostic factor in patients treated according to COALL or St Jude protocols. Blood (2006) 0.96

Childhood leukemia--new advances and challenges. N Engl J Med (2004) 0.96

NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet (2016) 0.93

Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics (2011) 0.93

Pharmacogenomics in pediatric leukemia. Curr Opin Pediatr (2010) 0.93

Protein kinase A (PKA) isoform RIIbeta mediates the synergistic killing effect of cAMP and glucocorticoid in acute lymphoblastic leukemia cells. J Biol Chem (2008) 0.92

A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm. Clin Pharmacol Ther (2013) 0.91

Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model. J Biol Chem (2014) 0.91

The synergism of MCL1 and glycolysis on pediatric acute lymphoblastic leukemia cell survival and prednisolone resistance. Haematologica (2013) 0.90

Cancer pharmacogenomics. Clin Pharmacol Ther (2011) 0.89

Molecular diagnosis and risk-adjusted therapy in pediatric hematologic malignancies: a primer for pediatricians. Eur J Pediatr (2011) 0.89

Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL. Leukemia (2013) 0.88

Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor. Nat Commun (2016) 0.88

Pharmacogenetics in acute lymphoblastic leukemia. Semin Hematol (2009) 0.88

External quality assessment of tumour marker analysis: state of the art and consequences for estimating diagnostic sensitivity and specificity. Ger Med Sci (2005) 0.88

Analysis of Patterns of Gene Expression Variation within and between Ethnic Populations in Pediatric B-ALL. Cancer Inform (2013) 0.88

Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood (2013) 0.87

Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia. Clin Med Insights Oncol (2014) 0.87

Digital gene expression profiling of primary acute lymphoblastic leukemia cells. Leukemia (2011) 0.87

The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia. Haematologica (2013) 0.86

Menin as a hub controlling mixed lineage leukemia. Bioessays (2012) 0.85

Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design. Clin Cancer Res (2016) 0.84

Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM. Neuro Oncol (2011) 0.84

IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study. PLoS Med (2016) 0.83

Anticancer drug sensitivity prediction in cell lines from baseline gene expression through recursive feature selection. BMC Cancer (2015) 0.82

Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2016) 0.82

RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics (2013) 0.81

Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. Oncotarget (2015) 0.81

DISIS: prediction of drug response through an iterative sure independence screening. PLoS One (2015) 0.81

A network flow-based method to predict anticancer drug sensitivity. PLoS One (2015) 0.81

Concordant gene expression in leukemia cells and normal leukocytes is associated with germline cis-SNPs. PLoS One (2008) 0.80

MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies. ISRN Hematol (2013) 0.80

Glucocorticoid-induced cell death is mediated through reduced glucose metabolism in lymphoid leukemia cells. Blood Cancer J (2011) 0.80

Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia. BMC Cancer (2009) 0.79

Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL). Transl Oncol (2015) 0.78

Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines. Sci Rep (2015) 0.78

Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020. Pharmacogenomics (2010) 0.78

Antenatal endogenous and exogenous glucocorticoids and their impact on immune ontogeny and long-term immunity. Semin Immunopathol (2016) 0.78

Resistance to chemotherapy is associated with altered glucose metabolism in acute myeloid leukemia. Oncol Lett (2016) 0.77

A unique complex translocation involving six different chromosomes in a case of childhood acute lymphoblastic leukemia with the Philadelphia chromosome and adverse prognosis. Oncol Lett (2010) 0.77

Pharmacological inhibition of fatty-acid oxidation synergistically enhances the effect of l-asparaginase in childhood ALL cells. Leukemia (2015) 0.77

Expression profiling of drug response--from genes to pathways. Dialogues Clin Neurosci (2006) 0.77

Influence of wild-type MLL on glucocorticoid sensitivity and response to DNA-damage in pediatric acute lymphoblastic leukemia. Mol Cancer (2010) 0.77

Articles by these authors

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68

MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet (2001) 13.79

Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83

Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54

BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89

Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95

Acute lymphoblastic leukemia. N Engl J Med (2004) 7.83

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol (2009) 5.22

Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89

Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89

FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med (2007) 4.59

Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41

Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35

The tumor lysis syndrome. N Engl J Med (2011) 4.29

Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21

Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell (2006) 3.93

Gene expression profiling of pediatric acute myelogenous leukemia. Blood (2004) 3.77

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol (2010) 3.76

Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell (2003) 3.75

CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature (2011) 3.72

Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet (2009) 3.71

Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med (2003) 3.57

Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet (2007) 3.48

The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43

Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2011) 3.40

Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol (2008) 3.34

Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. J Clin Oncol (2011) 3.05

Moving towards individualized medicine with pharmacogenomics. Nature (2004) 2.99

Pharmacogenomics and individualized drug therapy. Annu Rev Med (2006) 2.95

Direct ubiquitination of pattern recognition receptor FLS2 attenuates plant innate immunity. Science (2011) 2.93

Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell (2011) 2.89

Robust estimation of the false discovery rate. Bioinformatics (2006) 2.87

NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol (2010) 2.85

Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood (2012) 2.82

In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell (2008) 2.78

Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA (2003) 2.77

Improving false discovery rate estimation. Bioinformatics (2004) 2.77

Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA (2009) 2.72

Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital. Blood (2009) 2.70

PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet (2010) 2.66

Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med (2012) 2.60

Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood (2009) 2.57

Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia. Blood (2012) 2.56

Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood (2012) 2.55

Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol (2010) 2.52